Tommy Ritz is a William and Mary MBA who previously worked for Novo Nordisk (one of three major insulin producers) developing reimbursement models for Novo Nordisk’s prescription drugs. In 2017, due to his history of advocacy, Tommy was called in as an expert witness to testify on behalf of Ohio House Bill 241, the Diabetic Registry Bill. He currently works in supply chain management at Shell Oil. Tommy has been a type 1 diabetic since he was 5.
